Neuland Laboratories Q1 FY27: Strong commercial CMS execution, capex momentum, and peptides nearing commissioning

Neuland Laboratories reported a sharp jump in performance in Q1 FY27, driven largely by commercial CMS execution and a favorable mix. Total income for the quarter was INR 650.1 crore versus INR 300.6 crore in Q1 FY26, while EBITDA rose to INR 231.1 crore with a 35.5% margin. Profit after tax increased to INR 147.4 crore.

Management described the quarter as broadly in line with expectations, but repeatedly highlighted the inherently uneven nature of the company’s business model. The emphasis remained on assessing performance over longer periods rather than quarter-to-quarter comparisons.

What drove Q1 FY27

Two threads ran through management commentary.

First, the company’s commercial CMS programs continued to contribute the majority of revenue. Management stated that commercial CMS is still driven by a handful of molecules, with around three molecules doing most of the heavy lifting, and it expects these to remain active over the next five to six years.

Second, there were early signals of an improving development pipeline. Management said it has seen at least two new projects come in during FY27, described as fairly advanced in the clinic. It also indicated that some of these projects are peptides, which were not visualized a year earlier.

Within GDS, management called out products such as Ezetimibe, Mirtazapine, Escitalopram and Aripiprazole among key contributors in the quarter.

Financial summary (Standalone)

The CFO also disclosed gross margin of 61.2% in Q1 FY27 versus 55.3% in Q1 FY26.

Working capital and balance sheet: improved cash conversion

A key operational highlight was working capital efficiency. Working capital days improved to 84 days in Q1 FY27 from 137 days at the end of FY26, primarily due to a reduction in receivables.

On the balance sheet, the company reported net debt of negative INR 308.5 crore at the end of Q1 FY27, compared to negative INR 156.8 crore at the end of FY26. The investor presentation also reported current ratio of 2.2x at Q1 FY27.

Management framed optimal utilization of cash as an ongoing priority and highlighted its focus on inventory optimization and disciplined execution.

Capex cycle continues: R&D, peptides, and capacity expansion

Neuland remains in a high-investment phase.

In Q1 FY27, capex outflow was INR 121.6 crore (also stated as INR 122 crore in the presentation), primarily towards the new R&D and peptide facilities. During the quarter, the company approved additional capex of approximately INR 203 crore, of which INR 196 crore is earmarked for strategic growth initiatives, largely related to capacity expansion at Unit 1.

Management also disclosed that against total approved capex of INR 1,460 crore over the last 13 quarters, it has spent INR 870 crore to date, with the balance committed to projects under implementation.

The CEO said investment intensity could further increase based on the opportunities available, and later added that future investments could be both higher in quantum and qualitatively different. He specifically referenced a move towards newer modalities and noted that, for some modalities, overseas investment or M&A could become relevant.

Peptides: nearing commissioning, with early project visibility

Peptides were the clearest example of the company’s capability-building thesis.

Management said the peptide manufacturing plant is expected to be commissioned next month (from the Aug 5, 2026 call), after which manufacturing qualification will be completed. It also stated that it has order visibility for the peptide block and that a couple of projects are expected to use the facility even before commissioning.

While management did not quantify the potential peptide revenue, it described growing customer interest and said discussions have expanded, providing greater visibility around Module 1 utilization.

Sterile APIs via partnership: collaboration with Gland Pharma

The company also highlighted a strategic collaboration with Gland Pharma.

Management positioned this partnership as a way to create a platform in sterile APIs by combining complementary strengths: Neuland’s experience in complex APIs and Gland’s established sterile manufacturing capabilities and regulatory track record. It stated that the collaboration is aimed at niche generic molecules that require sterile manufacturing, and that partnering helps Neuland avoid the risks of operating sterile facilities independently.

What management is watching

Management said it continues to monitor geopolitical developments and global trade, and while it has not experienced a material impact on operations or customer commitments thus far, it remains vigilant.

It also addressed a prior concern around transcript manipulation, stating that the full unedited audio is available on the company’s website and that the transcript is prepared by an agency and edited for readability.

Takeaways

Q1 FY27 reinforced the company’s current operating reality and its direction of travel.

Commercial CMS programs remain the main earnings driver, and management acknowledged concentration in a handful of molecules. At the same time, working capital improvement and a net cash position add financial flexibility to sustain a heavy capex cycle.

The near-term milestones to track are execution consistency across commercial CMS, commissioning and qualification of the peptide facility, and how quickly new development wins begin translating into diversified commercial revenues over the next few years.